143 related articles for article (PubMed ID: 10421065)
1. Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1.
Osmak M; Vrhovec I; Skrk J
J Neurooncol; 1999 Apr; 42(2):95-102. PubMed ID: 10421065
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.
Go Y; Chintala SK; Rayford A; Gagercas E; Ali-Osman F; Venkaiah B; Sawaya R; Gokaslan Z; Nicolson GL; Rao JS
Clin Exp Metastasis; 1997 Jul; 15(4):447-52. PubMed ID: 9219734
[TBL] [Abstract][Full Text] [Related]
4. [A plasminogen regulation system in brain tumors].
Kit OI; Frantsiyants EM; Kozlova LS; Rostorguev EE; Balyazin-Parfenov IV; Pogorelova YA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(2):22-27. PubMed ID: 28524122
[TBL] [Abstract][Full Text] [Related]
5. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
7. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
8. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Kinder DH; Berger MS; Mueller BA; Silber JR
Oncol Res; 1993; 5(10-11):409-14. PubMed ID: 8054701
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Eur J Cancer; 1998 Jul; 34(8):1193-7. PubMed ID: 9849478
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Landau BJ; Kwaan HC; Verrusio EN; Brem SS
Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
[TBL] [Abstract][Full Text] [Related]
12. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
[TBL] [Abstract][Full Text] [Related]
13. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Arai Y; Kubota T; Nakagawa T; Kabuto M; Sato K; Kobayashi H
Acta Neurochir (Wien); 1998; 140(4):377-85; discussion 385-6. PubMed ID: 9689330
[TBL] [Abstract][Full Text] [Related]
14. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
15. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Arnoletti JP; Albo D; Granick MS; Solomon MP; Castiglioni A; Rothman VL; Tuszynski GP
Cancer; 1995 Sep; 76(6):998-1005. PubMed ID: 8625226
[TBL] [Abstract][Full Text] [Related]
18. Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis.
Osmak M; Niksíc D; Brozović A; Ristov AA; Vrhovec I; Skrk J
Anticancer Res; 1999; 19(4B):3193-7. PubMed ID: 10652611
[TBL] [Abstract][Full Text] [Related]
19. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]